Nymox Pharmaceutical Corporation
NYMXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.11M
Close$
$0.00
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.11 Million |
|---|---|
| Enterprise Value | $3.04 Million |
| Earnings per Share | $-0.04 |
| Beta | 8.9 |
| Outstanding Shares | 94,230,744 |
Return
| Return on Equity | 116.90% |
|---|---|
| Return on Assets | -1211.01% |
| Return on Invested Capital | 113.96% |
Valuation & Multiples
| P/E Ratio | -0.72 |
|---|---|
| PEG | 0.86 |
| Price to Sales | - |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.39 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Nymox Pharmaceutical Corp
16 employees
CEO: Paul Averback
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's fl...